statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Latest Ratings for HOOK
 DateFirmActionFromTo Feb 2022HC Wainwright & Co.MaintainsBuy Feb 2022SVB LeerinkMaintainsOutperform Nov 2021Morgan StanleyDowngradesOverweightEqual-Weight
 View More...

Breaking Down HOOKIPA Pharma: 4 Analysts Share Their Views

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Hookipa Pharma reports Q4 EPS (22c), consensus (19c)

Best-in-class preliminary Phase 2 data for HB-200 in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancers in the first line setting Expect updated Phase...

HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Roy Buchanan, an analyst from JMP Securities, reiterated the Buy rating on Hookipa Pharma (HOOK Research Report). The associated price target is...

Buy Rating Affirmed for Hookipa Pharma on Emerging Oncology and Infectious Disease Pipelines

HOOKIPA Pharma: Q4 Earnings Insights

NEW YORK and VIENNA, Austria, March 06, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, 'HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary...

HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference

Hookipa Pharma to reduce workforce by 30%

Hookipa Pharma announces focus on two strategic areas

HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious disease HOOKIPA will regain global development...

HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs

NEW YORK and VIENNA, Austria, Jan. 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, 'HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary...

HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer  to Lead Clinical Research and Development Organization

HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The firm also focuses on immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company was founded by Rolf M. Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel D. Pinschewer in 2011 and is headquartered in New York, NY.

Volume	427,693.00
52-Wk High	$2.05
52-Wk Low	$0.41

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.10	--	--	N/A
Q4'23	-$0.19	-$0.22	-17.86%	MISSED
Q3'23	-$0.21	-$0.17	19.05%	BEAT
Q2'23	-$0.21	-$0.22	-5.60%	MISSED
Q1'23	-$0.23	-$0.27	-19.47%	MISSED

HOOK Hookipa Pharma Inc

About

Feed

News

Earnings

Fundamentals